Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
What is the rationale for early DMARD therapy once the diagnosis of RA is established?
What is the rationale for early DMARD therapy once the diagnosis of RA is established?
Video
Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?
Video
What are the triggers for using a biologic agent? How early in the course of the disease is initiation with a TNFI or IL-6 inhibitor warranted?
Video
How should one optimally “sequence” therapy in patients who require biologic therapy? Is there a “one-sequence-fits-all” strategy?
Video
What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials? And what is the role of treat-to-target?
Video
When, for reasons of toleration, combination therapy with methotrexate is not possible, what is the role of biologic agents, including IL-6 inhibitors, as part of monotherapeutic regimen?
Video
What patient types or clinical scenarios—sex of patient, aggressiveness of disease, poor treatment response, host risk factors, history of response, etc.—are ideally aligned with agents targeting IL-6?
Video
What do you think are some of the most important unmet needs in RA?
What do you think are some of the most important unmet needs in RA?
Video
What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials?
Video
What do studies and guidelines suggest as successful therapeutic strategies for RA patients who have been inadequate responders to TNF therapy? On the basis of what criteria is the decision made to switch to an Il-6 inhibitor or an agent ...
Video
And how do you approach the biologically naive patient?
And how do you approach the biologically naïve patient?
Video
Is there a “one-sequence-fits-all” strategy? Or can one start with any of the biologic agents as an initial therapy in conjunction with methotrexate?